Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma

BACKGROUND: Hepatitis B virus (HBV) reactivation is commonly seen in HBsAg-positive hematologic patients undergoing immunosuppressive chemotherapy. Little is known about the risk of HBV reactivation after chimeric antigen receptor T-cell (CAR T) immunotherapy for the treatment of refractory/relapsed...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jia, Zhu, Xiaojian, Mao, Xia, Huang, Liang, Meng, Fankai, Zhou, Jianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868854/
https://www.ncbi.nlm.nih.gov/pubmed/31753002
http://dx.doi.org/10.1186/s40425-019-0790-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868854/
https://www.ncbi.nlm.nih.gov/pubmed/31753002
http://dx.doi.org/10.1186/s40425-019-0790-y

Ejemplares similares